Monday 23rd September 2019
Botox surgery is emerging as a form of treatment for Raynaud’s phenomenon, but the reasoning behind why this may work remains unclear. Research evaluating the use of Botulinum toxin type A (BoNT/A), one of the the main ingredients of Botox, has been steadily building since the early 2000s.
Friday 13th September 2019
In an exciting step for scleroderma treatment, the USA’s Food and Drug Administration (FDA) have approved the use of nintedanib in treating interstitial lung disease associated with systemic sclerosis, making this the first therapy for those living with this condition caused by lung fibrosis.
Friday 6th September 2019
Many of our community will understand the difficulties that come with trying to secure disability benefits. As scleroderma is still a little known illness, it can take some hard work to secure the benefits you are entitled to. To help you figure out how to approach the process, we’ve asked members of our community to share their experiences.
Thursday 27th September 2018
Lucy Sephton, diagnosed with scleroderma 16 years ago, talks about how proud she is of her daughter for raising a staggering £4,388 for SRUK by chopping her hair for charity.
Tuesday 25th September 2018
SRUK have made a significant contribution in providing funding for this two-year pilot study, which is well underway. Initial results are promising, and the success of the study means that the implantable loop recorder can then be examined through a wider clinical study.
Friday 21st September 2018
Dr. Victoria Flower, based in Bath, is working on a new research project, fully entitled, ‘The role of Hypoxia Inducible Factor and Vascular Endothelial Growth Factor in microvascular dysfunction and fibrosis in Systemic sclerosis’, to examine factors that may be affecting blood flow in people with Scleroderma and Raynaud’s.
Monday 17th September 2018
Scleroderma & Raynaud’s UK (SRUK) has been awarded a consultation with The Difference Collective to enhance current communications. SRUK will get the chance to pick the brains of up to 10 of the Collectives top healthcare comms experts during a free one-hour brainstorming session.
Friday 14th September 2018
A team led by Sabrina Munir at King’s College London has found that the presence of single nucleotide polymorphisms (SNPs) may be indicative of Raynaud's Phenomenon or act as a measure of how likely the individual is to develop the condition.
Thursday 6th September 2018
Initially diagnosed with fibromyalgia, Lauren had actually developed a very aggressive form of scleroderma. Her condition worsened and after a harrowing 3 weeks in intensive care, she died of acute renal crisis and accelerated hypertension. Her father Philip tells her story.
Wednesday 28th September 2016
The FDA has granted Orphan Drug Designation to Boehringer Ingelheim’s nintedanib for the treatment of systemic sclerosis (SSc), also known as scleroderma, including associated interstitial lung disease (SSc-ILD). - See more at: http://www.pharmacytimes.com/product-news/nintedanib-receives-orphan-drug-designation-for-systemic-sclerosis#sthash.5ACj39Ga.dpuf
